BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 17569962)

  • 1. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Cha S; Lupo JM; Chen MH; Lamborn KR; McDermott MW; Berger MS; Nelson SJ; Dillon WP
    AJNR Am J Neuroradiol; 2007; 28(6):1078-84. PubMed ID: 17569962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Barajas RF; Chang JS; Segal MR; Parsa AT; McDermott MW; Berger MS; Cha S
    Radiology; 2009 Nov; 253(2):486-96. PubMed ID: 19789240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases.
    Mouthuy N; Cosnard G; Abarca-Quinones J; Michoux N
    J Neuroradiol; 2012 Dec; 39(5):301-7. PubMed ID: 22197404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
    Bauer AH; Erly W; Moser FG; Maya M; Nael K
    Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
    Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
    Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
    AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.
    Barajas RF; Phillips JJ; Parvataneni R; Molinaro A; Essock-Burns E; Bourne G; Parsa AT; Aghi MK; McDermott MW; Berger MS; Cha S; Chang SM; Nelson SJ
    Neuro Oncol; 2012 Jul; 14(7):942-54. PubMed ID: 22711606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Xing Z; You RX; Li J; Liu Y; Cao DR
    Clin Neuroradiol; 2014 Dec; 24(4):329-36. PubMed ID: 23994941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma multiforme versus solitary supratentorial brain metastasis: differentiation based on morphology and magnetic resonance signal characteristics.
    Maurer MH; Synowitz M; Badakshi H; Lohkamp LN; Wüstefeld J; Schäfer ML; Wiener E
    Rofo; 2013 Mar; 185(3):235-40. PubMed ID: 23196836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of MR perfusion parameters in differentiation between glioblastoma recurrence and radiation necrosis.
    Bobek-Billewicz B; Heinze S; Awramienko-Wloczek A; Majchrzak K; Nowicka E; Hebda A
    Folia Neuropathol; 2023; 61(4):371-378. PubMed ID: 38282486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral peritumoral oedema study: does a single dynamic MR sequence assessing perfusion and permeability can help to differentiate glioblastoma from metastasis?
    Lehmann P; Saliou G; de Marco G; Monet P; Souraya SE; Bruniau A; Vallée JN; Ducreux D
    Eur J Radiol; 2012 Mar; 81(3):522-7. PubMed ID: 21334839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation between brain glioblastoma multiforme and solitary metastasis: qualitative and quantitative analysis based on routine MR imaging.
    Chen XZ; Yin XM; Ai L; Chen Q; Li SW; Dai JP
    AJNR Am J Neuroradiol; 2012 Nov; 33(10):1907-12. PubMed ID: 22743640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Barajas RF; Chang JS; Sneed PK; Segal MR; McDermott MW; Cha S
    AJNR Am J Neuroradiol; 2009 Feb; 30(2):367-72. PubMed ID: 19022867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR perfusion-weighted imaging may help in differentiating between nonenhancing gliomas and nonneoplastic lesions in the cervicomedullary junction.
    Liu X; Kolar B; Tian W; Germin BI; Huang Y; Hu R; Zhong J; Ekholm S
    J Magn Reson Imaging; 2011 Jul; 34(1):196-202. PubMed ID: 21618332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
    Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
    Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.